The report provides an overview of PPMS in detail, highlights the PPMS epidemiology in the key geographies, elaborates on the drugs prescribed and expected to be prescribed in PPMS and covers the detailed market sizing drug wise and country wise in value sales and patient numbers along with forecasts. The report elaborates on the Primary Progressive Multiple Sclerosis (PPMS) disease indication detailing the definition, causes, profile of a PPMS patient, symptoms of a PPMS patient, and disease progression in a PPMS patient.
The report further highlights the multiple methods through which the patient can be diagnosed for PPMS. The next part of the report consists of PPMS epidemiology and prevalence in the key geographies across the globe such as the US, UK, Germany, Italy, France, Spain and Japan. The epidemiology for PPMS indication across key geographies has been forecast to 2024. The next part of the report highlights the importance of factors influencing physician prescription decisions in PPMS like efficacy factors, tolerability factors, monitoring requirements and pricing factors.
The report further details the drugs prescribed or expected to be prescribed in PPMS by physicians in terms of details about the formulation, molecule, mode of administration and MoA of the drugs, their patent and trial details and the expected impact of the drug in the PPMS market. The report further details the drug attribute analysis drug wise on each parameter considered important in the prescription of PPMS drugs. The report also covers the other products which are currently in the pipeline for PPMS and other progressive forms of MS. The final part of the report gives a detailed overview of PPMS market sizing drug wise and geography wise both in terms of value sales and patient numbers. The drugs have been forecast to 2030 both for value sales and patient numbers geography wise.